{"artifact":{"id":"rsc-h-796cfd1c-113c9c13","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation","quality_score":0.3,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-796cfd1c\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable, sex-specific analyses, or consideration of sex differences in the mechanistic or therapeutic claims.","location":"Not applicable"},"blinding":{"score":1,"evidence":"No study is described; therefore, no blinding procedures are applicable or reported.","location":"Not applicable"},"study_design":{"score":1,"evidence":"The hypothesis proposes a therapeutic target without describing any actual study design, methods, population, or experimental approach to test its claims.","location":"Entire text"},"power_analysis":{"score":1,"evidence":"No study is described; therefore, no statistical power calculations or sample size justifications are reported.","location":"Not applicable"},"data_availability":{"score":1,"evidence":"No data or code availability statements are provided in this hypothesis text.","location":"Not applicable"},"scientific_premise":{"score":3,"evidence":"Acid sphingomyelinase (ASM/SMPD1) is elevated in Alzheimer disease brains, leading to reduced sphingomyelin and elevated ceramide accumulation within membrane microdomains.","location":"Opening paragraph"},"statistical_reporting":{"score":2,"evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments (p=1.51e-06)","location":"STRING enrichment paragraph"},"resource_identification":{"score":2,"evidence":"OLX-070 (Obsidian Therapeutics) are currently in Phase I/II trials for AD (NCT06748821)","location":"Preclinical evidence paragraph"}},"overall_summary":"This text is a therapeutic hypothesis/position statement rather than a study report, making traditional rigor dimensions partially inapplicable. It provides moderate scientific premise through genetic and mechanistic citations but lacks any experimental design, statistical methodology, or resource identification beyond high-level references to clinical trials. The hypothesis appropriately acknowledges prior translational failures but fails to address sex as a biological variable.","weakest_dimension":"study_design","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"SMPD1 knockout is lethal in mice, and complete SMPD1 inhibition causes Niemann-Pick disease in humans","location":"Fourth paragraph"},"blinding":{"score":1,"evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments","location":"Second paragraph"},"study_design":{"score":1,"evidence":"SMPD1 knockout is lethal in mice, and complete SMPD1 inhibition causes Niemann-Pick disease in humans, indicating that only partial inhibition may be achievable and clinically tolerable.","location":"Fourth paragraph"},"power_analysis":{"score":1,"evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1","location":"Second paragraph"},"data_availability":{"score":1,"evidence":"Aβ oligomers activate ASM, establishing a feedforward cycle of ceramide accumulation that correlates with Aβ peptide levels in affected brains.","location":"First paragraph"},"scientific_premise":{"score":3,"evidence":"Acid sphingomyelinase (ASM/SMPD1) is elevated in Alzheimer disease brains, leading to reduced sphingomyelin and elevated ceramide accumulation within membrane microdomains. SMPD1 genetic association with AD is supported by Open Targets (score 0.5417), providing independent genetic validation for this therapeutic target.","location":"First paragraph"},"statistical_reporting":{"score":2,"evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments (p=1.51e-06)","location":"Second paragraph"},"resource_identification":{"score":1,"evidence":"Preclinical evidence includes ARC39-mediated ASM inhibition enhancing GABAergic inhibitory synaptic drive onto CA1 pyramidal cells, and amitriptyline (FIASMA) demonstrating neuroprotective effects in tauopathy through functional ASM inhibition and ceramide reduction.","location":"Third paragraph"}},"overall_summary":"This text presents a hypothesis rationalizing SMPD1 as a therapeutic target for Alzheimer's disease but fundamentally lacks the structural elements of a research report. While it demonstrates adequate scientific premise with genetic and enrichment evidence, it omits critical methodological reporting—blinding, power analysis, resource identification with RRIDs, statistical test details, data availability statements, and SABV consideration are entirely absent. The text functions as a therapeutic target justification rather than a research report.","weakest_dimension":"study_design","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators provided consistent scores across all 8 dimensions with no flagged disagreements (all |A-B| ≤ 1). For resource_identification, A scored 2 (citing OLX-070 in Phase I/II trials) while B scored 1 (citing preclinical agents without RRIDs), resulting in an average of 2. All evidence quotes are valid (>10 characters). The text is a therapeutic hypothesis/position statement rather than a study report; evaluators correctly identified the inherent limitations for dimensions requiring experimental methodology (blinding, power analysis, data availability). Scientific_premise was the strongest dimension (score 3) with adequate genetic and mechanistic evidence, while study_design was the weakest (score 1) due to the absence of any actual study methodology. Cohen's kappa of 0.43 reflects moderate agreement accounting for chance, consistent with the evaluators independently identifying the same methodological gaps despite citing different evidence passages.","overall_agreement":"medium","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex as a biological variable, sex-specific analyses, or consideration of sex differences in the mechanistic or therapeutic claims.","b_evidence":"SMPD1 knockout is lethal in mice, and complete SMPD1 inhibition causes Niemann-Pick disease in humans","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No study is described; therefore, no blinding procedures are applicable or reported.","b_evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments","disagreement":false},"study_design":{"score":1,"a_score":1,"b_score":1,"a_evidence":"The hypothesis proposes a therapeutic target without describing any actual study design, methods, population, or experimental approach to test its claims.","b_evidence":"SMPD1 knockout is lethal in mice, and complete SMPD1 inhibition causes Niemann-Pick disease in humans, indicating that only partial inhibition may be achievable and clinically tolerable.","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No study is described; therefore, no statistical power calculations or sample size justifications are reported.","b_evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No data or code availability statements are provided in this hypothesis text.","b_evidence":"Aβ oligomers activate ASM, establishing a feedforward cycle of ceramide accumulation that correlates with Aβ peptide levels in affected brains.","disagreement":false},"scientific_premise":{"score":3,"a_score":3,"b_score":3,"a_evidence":"Acid sphingomyelinase (ASM/SMPD1) is elevated in Alzheimer disease brains, leading to reduced sphingomyelin and elevated ceramide accumulation within membrane microdomains.","b_evidence":"Acid sphingomyelinase (ASM/SMPD1) is elevated in Alzheimer disease brains, leading to reduced sphingomyelin and elevated ceramide accumulation within membrane microdomains. SMPD1 genetic association with AD is supported by Open Targets (score 0.5417), providing independent genetic validation for this therapeutic target.","disagreement":false},"statistical_reporting":{"score":2,"a_score":2,"b_score":2,"a_evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments (p=1.51e-06)","b_evidence":"STRING enrichment analysis confirms a statistically significant cluster of SMPD1 with FLOT1, FLOT2, BACE1, APP, LRP1, and CAV1 in membrane raft compartments (p=1.51e-06)","disagreement":false},"resource_identification":{"score":2,"a_score":2,"b_score":1,"a_evidence":"OLX-070 (Obsidian Therapeutics) are currently in Phase I/II trials for AD (NCT06748821)","b_evidence":"Preclinical evidence includes ARC39-mediated ASM inhibition enhancing GABAergic inhibitory synaptic drive onto CA1 pyramidal cells, and amitriptyline (FIASMA) demonstrating neuroprotective effects in tauopathy through functional ASM inhibition and ceramide reduction.","disagreement":false}},"inter_rater_agreement":"0.43","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-796cfd1c","scored_entity_type":"hypothesis","scored_entity_title":"SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation"},"created_at":"2026-04-22T14:01:26.968096-07:00","updated_at":"2026-04-22T14:01:26.968101-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-22T14:01:26.968096-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"6369f17c-dfcb-4c75-b0e4-39d2217e67c1","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"analysis-SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2","link_type":"derives_from","strength":1.0,"evidence":"rigor_score_card.scored_entity=h-796cfd1c -> hypotheses.analysis_id=SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2"}],"incoming_links":[],"current_artifact_id":"rsc-h-796cfd1c-113c9c13","is_canonical":true,"supersede_chain":["rsc-h-796cfd1c-113c9c13"]}